See more : Canadian Nexus Team Ventures Corp. (LGMFF) Income Statement Analysis – Financial Results
Complete financial analysis of Piramal Pharma Limited (PPLPHARMA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Piramal Pharma Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Hotel Property Investments (HPI.AX) Income Statement Analysis – Financial Results
- Ion Exchange (India) Limited (IONEXCHANG.BO) Income Statement Analysis – Financial Results
- Morguard Corporation (MRC.TO) Income Statement Analysis – Financial Results
- Lifa Air Oyj (LIFA.HE) Income Statement Analysis – Financial Results
- Nordea Invest Global Stars (NDIGSTKL1.CO) Income Statement Analysis – Financial Results
Piramal Pharma Limited (PPLPHARMA.NS)
Industry: Biotechnology
Sector: Healthcare
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 81.71B | 70.82B | 30.95B | 29.39B |
| Cost of Revenue | 32.62B | 27.03B | 15.49B | 12.78B |
| Gross Profit | 49.09B | 43.78B | 15.46B | 16.61B |
| Gross Profit Ratio | 60.08% | 61.83% | 49.95% | 56.50% |
| Research & Development | 1.01B | 863.60M | 619.40M | 691.40M |
| General & Administrative | 2.63B | 2.32B | 607.80M | 538.50M |
| Selling & Marketing | 3.04B | 3.21B | 1.75B | 1.28B |
| SG&A | 5.67B | 5.52B | 2.36B | 1.81B |
| Other Expenses | 41.80B | 2.25B | 654.10M | 153.00M |
| Operating Expenses | 48.48B | 44.27B | 12.78B | 11.80B |
| Cost & Expenses | 76.51B | 71.30B | 28.27B | 24.58B |
| Interest Income | 103.80M | 16.40M | 283.80M | 207.00M |
| Interest Expense | 4.47B | 3.44B | 1.98B | 47.10M |
| Depreciation & Amortization | 7.41B | 6.77B | 5.86B | 609.60M |
| EBITDA | 13.67B | 8.46B | 12.10B | 6.11B |
| EBITDA Ratio | 16.73% | 12.82% | 13.25% | 20.80% |
| Operating Income | 4.32B | 141.50M | 5.60B | 5.50B |
| Operating Income Ratio | 5.28% | 0.20% | 18.10% | 18.73% |
| Total Other Income/Expenses | -2.52B | -721.80M | -1.34B | 1.36B |
| Income Before Tax | 1.79B | -1.20B | 4.24B | 6.87B |
| Income Before Tax Ratio | 2.19% | -1.70% | 13.71% | 23.37% |
| Income Tax Expense | 1.61B | 663.10M | 811.80M | 1.15B |
| Net Income | 178.20M | -1.86B | 3.76B | 5.72B |
| Net Income Ratio | 0.22% | -2.63% | 12.15% | 19.45% |
| EPS | 0.14 | -1.53 | 3.11 | 4.68 |
| EPS Diluted | 0.14 | -1.53 | 3.11 | 4.68 |
| Weighted Avg Shares Out | 1.27B | 1.22B | 1.21B | 1.22B |
| Weighted Avg Shares Out (Dil) | 1.28B | 1.22B | 1.21B | 1.22B |
Source: https://incomestatements.info
Category: Stock Reports